SGP Stock News & Catalysts

FEATURED

SpyGlass Pharma to Participate in Upcoming Investor Conferences

IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company, today announced that members of the

Summary

Nov 5, 2026, 8:00 AM ·Globe Newswire

RECENT

SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System

Groundbreaking 4-year safety and efficacy results: 37% reduction in mean intraocular pressure (IOP) across all dose groups86% of patients remained off all topical IOP-lowering drops90% of patients maintained ≥20/25

Oct 19, 2026, 8:00 AM ·Globe Newswire

SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability

SpyGlass Pharma acquires 100% of the outstanding shares of AVS, a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), the existing manufacturer of SpyGlass Pharma’s intraocular lens (IOL)Secures scalable commercial

Oct 1, 2026, 8:00 AM ·Globe Newswire

SpyGlass Pharma to Participate in Upcoming Investor Conferences

IRVINE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company, today announced that members of the

Sep 2, 2026, 8:00 AM ·Globe Newswire

SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.Bimatoprost-Drug Ring System (BIM-DRS)

Aug 6, 2026, 4:05 PM ·Globe Newswire

SpyGlass Pharma Appoints Shannon Treviño as General Counsel

ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of Shannon Treviño as

Jun 15, 2026, 8:00 AM ·Globe Newswire

SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing

ALISO VIEJO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced the appointment of Mike Pinder as vice president,

Jun 2, 2026, 8:00 AM ·Globe Newswire

SpyGlass Pharma to Participate in Upcoming Investor Conferences

ALISO VIEJO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company, today announced that members of the executive

May 21, 2026, 8:00 AM ·Globe Newswire

SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System

ALISO VIEJO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced that the American Medical Association's (AMA)

May 18, 2026, 8:00 AM ·Globe Newswire

SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.Topline 12-month data from the BIM-IOL System Phase

May 14, 2026, 4:05 PM ·Globe Newswire

SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update

Successfully completed Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq.Reported positive topline 12-month data from Phase 1/2 trial of the Bimatoprost Drug Pad-IOL System

Mar 26, 2026, 4:05 PM ·Globe Newswire

SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System

97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20 vision, demonstrating

Mar 9, 2026, 8:00 AM ·Globe Newswire

SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit

ALISO VIEJO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma"), a late-stage biopharmaceutical company, today announced that members of the executive management team will

Mar 4, 2026, 8:00 AM ·Globe Newswire

SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

ALISO VIEJO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma"), a late-stage biopharmaceutical company, today announced the closing of its initial public offering of

Feb 9, 2026, 4:05 PM ·Globe Newswire

SpyGlass Pharma Announces Pricing of Initial Public Offering

ALISO VIEJO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma"), a late-stage biopharmaceutical company, today announced the pricing of its initial public offering of

Feb 5, 2026, 7:00 PM ·Globe Newswire

SpyGlass Pharma, Inc. Common Stock SGP · News